We’re proud to recognize the outstanding work of our very own Dr. Sharma for his role in advancing innovative cancer treatments. His participation in the clinical trial of COM503 marks another step forward in the fight against advanced solid tumors. This Phase 1 trial is exploring the impact of COM503 as both a monotherapy and in combination with Zimberelimab. Congratulations to Dr. Sharma and the entire research team for their commitment to pushing the boundaries of cancer care. Read the full article here.